Germany's BioNTech (22UAy.DE) should be able to adapt its coronavirus vaccine relatively quickly in response to the emergence of the Omicron variant, its CEO Ugur Sahin told the Reuters Next conference on Friday. BioNTech and Pfizer Inc (PFE.N) together produced one of the first vaccines against COVID-19 and Sahin also said that vaccines should continue to provide protection against severe disease, despite mutations, Reuters said. "This variant might be able ...